<DOC>
	<DOCNO>NCT00001032</DOCNO>
	<brief_summary>PRIMARY : To determine safety , tolerance , pharmacokinetics zidovudine ( AZT ) zalcitabine ( dideoxycytidine ; ddC ) give combination clinically stable AZT-treated child . SECONDARY : To compare combination therapy mono drug therapy antiviral activity laboratory marker disease progression , determine virologic immunologic determination . To evaluate influence combination therapy disease progression determine evaluation clinical criterion . In child currently treat AZT , unknown whether addition another antiretroviral agent ddC would help increase efficacy tolerance . This study examine possible advantage combination AZT/ddC therapy monotherapy AZT alone .</brief_summary>
	<brief_title>A Study Dideoxycytidine Plus Zidovudine ( AZT ) HIV-Infected Children Who Have Taken AZT</brief_title>
	<detailed_description>In child currently treat AZT , unknown whether addition another antiretroviral agent ddC would help increase efficacy tolerance . This study examine possible advantage combination AZT/ddC therapy monotherapy AZT alone . Patients stratify accord duration ongoing AZT therapy randomize receive AZT either alone combination ddC . Patients receive therapy last patient enrol completes 32 week therapy . The study may extend two additional 32-week period optional basis .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Zalcitabine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Recommended : PCP prophylaxis . Allowed : Intravenous and/or intramuscular immunoglobulin . Acyclovir ( 30 mg/kg/day PO ) . Ketoconazole ( 10 mg/kg/day ) . Nystatin . Aspirin , acetaminophen , nonsteroidal antiinflammatory drug , sedative , barbiturate , exceed 72 hour . Isoniazid combination pyridoxine , provide evidence peripheral neuropathy . Trimethoprim / sulfamethoxazole . Amphotericin B ( 1 mg/kg 5 days/week ) . Aerosolized ribavirin bronchiolitis . Hematopoietic agent . Other drug little nephro , hepato , cytotoxicity . Nutritional support HIV waste syndrome malnutrition . Patients must : HIV infection . Ongoing stable AZT therapy . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Disease progression AZT , extent patient meet criteria advanced disease protocol . Known allergy sensitivity ddC . Cardiomyopathy . Concurrent Medication : Excluded : Biologic modifier IVIG , steroid , hematopoietic agent . Investigational medication unless approve protocol chair . Medications know cause pancreatitis ( unless ddC interrupted medication give ) . Patients follow prior condition exclude : History intolerance toxicity AZT . History symptomatic pancreatitis . History peripheral neuropathy abnormal nerve conduction velocity test . Prior Medication : Excluded : Antiretroviral agent AZT within 2 week study entry . Required : Ongoing stable AZT therapy 6 week duration .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Zalcitabine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
</DOC>